Oak Ridge Investments LLC Decreases Stake in Prothena Corporation PLC (PRTA)
Oak Ridge Investments LLC reduced its holdings in Prothena Corporation PLC (NASDAQ:PRTA) by 29.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 287,656 shares of the biotechnology company’s stock after selling 117,720 shares during the period. Oak Ridge Investments LLC owned approximately 0.75% of Prothena Corporation PLC worth $18,631,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of PRTA. BlackRock Inc. lifted its stake in shares of Prothena Corporation PLC by 95,458.7% in the first quarter. BlackRock Inc. now owns 2,733,934 shares of the biotechnology company’s stock worth $152,526,000 after buying an additional 2,731,073 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Prothena Corporation PLC by 186.0% during the second quarter. Westfield Capital Management Co. LP now owns 684,160 shares of the biotechnology company’s stock worth $37,027,000 after purchasing an additional 444,966 shares during the period. Woodford Investment Management Ltd raised its stake in Prothena Corporation PLC by 2.6% during the second quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock worth $616,991,000 after purchasing an additional 294,213 shares during the period. PointState Capital LP purchased a new position in Prothena Corporation PLC during the second quarter worth about $14,748,000. Finally, State Street Corp raised its stake in Prothena Corporation PLC by 10.6% during the second quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock worth $63,932,000 after purchasing an additional 113,193 shares during the period.
In related news, insider Tara Nickerson sold 17,500 shares of Prothena Corporation PLC stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $63.60, for a total value of $1,113,000.00. Following the completion of the transaction, the insider now owns 19,500 shares in the company, valued at $1,240,200. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Christopher S. Henney sold 900 shares of Prothena Corporation PLC stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total transaction of $63,000.00. Following the completion of the transaction, the director now owns 900 shares of the company’s stock, valued at approximately $63,000. The disclosure for this sale can be found here. Insiders sold 29,424 shares of company stock valued at $1,922,787 in the last 90 days. Company insiders own 3.10% of the company’s stock.
PRTA has been the topic of a number of analyst reports. ValuEngine raised shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Deutsche Bank AG set a $73.00 target price on shares of Prothena Corporation PLC and gave the stock a “buy” rating in a research note on Monday, October 23rd. Zacks Investment Research raised shares of Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 target price on the stock in a research note on Friday, August 11th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $79.00 target price on shares of Prothena Corporation PLC in a research note on Thursday, September 28th. Finally, Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $70.00 target price on shares of Prothena Corporation PLC in a research note on Thursday, November 9th. One investment analyst has rated the stock with a sell rating and fourteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $78.58.
TRADEMARK VIOLATION NOTICE: “Oak Ridge Investments LLC Decreases Stake in Prothena Corporation PLC (PRTA)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/oak-ridge-investments-llc-decreases-stake-in-prothena-corporation-plc-prta/1709662.html.
Shares of Prothena Corporation PLC (NASDAQ PRTA) traded down $0.31 on Friday, hitting $54.81. 405,500 shares of the company’s stock were exchanged, compared to its average volume of 290,095. Prothena Corporation PLC has a 1-year low of $45.13 and a 1-year high of $70.00.
Prothena Corporation PLC (NASDAQ:PRTA) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.41) by $0.04. The firm had revenue of $0.19 million during the quarter, compared to analysts’ expectations of $0.28 million. Prothena Corporation PLC had a negative net margin of 562.19% and a negative return on equity of 34.40%. The business’s quarterly revenue was down 33.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($1.26) earnings per share. equities research analysts anticipate that Prothena Corporation PLC will post -4.22 EPS for the current year.
Prothena Corporation PLC Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.